Researchers at Cardiff University have published a review about cancer treatment stating that taking low doses of aspirin during routine cancer therapy increases the chances of surviving patients by 20% and helps prevent metastasis. The article of scientists is published in the PLOS ONE magazine.
Researchers say that there is increasing evidence that low enough doses of aspirin have a remarkable positive effect in reducing the growth of some types of cancer. But it remains unknown what biochemical determines its role.
To clarify this, the authors of the article conducted an analysis of the currently available scientific literature. Scientists have studied the results of about fifty studies of colorectal cancer, breast cancer, and prostate cancer. They found that combined with other types of therapy, taking aspirin contributed to reducing mortality by about 15-20 percent and also reduced the incidence of malignancies formations.
Other types of cancer also found to be vulnerable to the preparation, but the small number of patients did not allow the authors to say this with confidence. Interestingly, researchers also found a link between the effect of aspirin drinking and mutations in the PIK3CA gene, which is present in 20% of the patients.
In addition, because one of the possible side effects of aspirin is gastrointestinal hemorrhage, the researchers asked for additional data from the authors of the analyzed studies. It was found that serious or dangerous bleeding was not observed in any of the cases.
The review highlights the need for future randomized trials to confirm the role of aspirin in cancer treatment and to define the mechanisms for its action.
Randomized study is an experiment where all participants are divided into two groups, one in which the investigated intervention is performed, and the other in the volunteers receiving a placebo. For more interesting information, check the other articles in our website.